Verastem, Inc.

VSTM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-209.5M $-130.6M $-87.4M $-73.8M $-71.2M $-67.7M $-149.2M $-72.4M
Depreciation & Amortization
Depreciation $30.0K $26.0K $62.0K $118.0K $206.0K $531.0K $429.0K $996.0K
Amortization $698.0K $793.0K $1.6M $423.0K
Stock-Based Compensation $9.4M $7.3M $5.9M $6.0M $7.7M $8.1M $8.5M $6.7M
Net Cash from Operating Activities $-137.5M $-104.8M $-86.5M $-63.7M $-53.5M $-33.5M $-138.5M $-74.5M
Investing Activities
Capital Expenditures $28.0K $196.0K $33.0K $7.0K $1.5M
Business Acquisitions
Net Cash from Investing Activities $-9.6M $60.0M $-44.4M $66.2M $87.0K $-47.4M $89.6M $-138.4M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $263.3M $54.8M $134.2M $51.8M $6.9M $69.6M $-2.4M $261.2M
Net Change in Cash $116.2M $10.0M $3.3M $54.3M $-46.5M $-11.2M $-51.3M $48.3M
Free Cash Flow $-104.8M $-53.7M $-33.5M $-138.5M $-76.0M
← Newer Page 1 of 2 Older →